Fresenius SE & Co. (OTCMKTS:FSNUY) Stock Short Interest Jumps 1,170.7%

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 367,297 shares, a growth of 1,170.7% from the September 30th total of 28,906 shares. Based on an average trading volume of 1,015,424 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.0% of the company’s shares are sold short.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating. Based on data from MarketBeat, Fresenius SE & Co. currently has a consensus rating of “Buy”.

Fresenius SE & Co. Stock Performance

Shares of FSNUY stock opened at $12.99 on Tuesday. The firm has a 50 day moving average of $12.95 and a two-hundred day moving average of $12.91. The stock has a market capitalization of $29.27 billion, a PE ratio of 16.44 and a beta of 0.60. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.41. Fresenius SE & Co. has a 52 week low of $10.33 and a 52 week high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. The company had revenue of $6.91 billion for the quarter, compared to analysts’ expectations of $6.65 billion. On average, research analysts predict that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.